References in periodicals archive ?
The NCOA3 gene is located on a region of chromosome 20 that's often amplified in human breast cancer.
NCOA3 immunostaining was scored by a dermatopathologist blinded as to patient outcome.
The relapse rate was 52% in patients whose primary tumors had high NCOA3 expression, compared with 36% in those with low or no NCOA3.
In a multivariate Cox regression analysis, NCOA3 expression was an independent predictor of both disease-specific survival and sentinel lymph node status.
But with overexpression of NCOA3 and osteopontin providing two new predictors of lymph node metastasis, it becomes possible to identify a subset of patients with thin or desmoplastic melanoma in whom sentinel node biopsy is warranted.
He and his colleagues have used a biologic agent targeting NCOA3 overexpression to treat mice with melanoma.
The co-activator NCOA3, also known as amplified in breast cancer-1 (AIB1) is overexpressed in 50% of breast cancers and amplified in 5% .
De esta manera se han encontrado amplificaciones en algunos de esos genes y se ha observado hasta el momento que su presencia en ciertas poblaciones podria estar contribuyendo a aumentar el riesgo a padecer: enfermedad bipolar cuando hay amplificacion en el gen SEF2-1B, OMIM 602272; autismo cuando estan en el gen RELN, OMIM 600514; sindrome de Jacobsen en el gen CBL2, OMIM 147791; cancer de ovarios en el gen hRAS1, OMIM 190020 y cancer de prostata en el gen NCOA3, OMIM 601937 (Anonimo 2004).
Medical browser ?
Full browser ?
- NCO Group
- NCO I/C
- NCO LANT
- NCO Leaders Skill Inventory
- NCO MED
- NCO PAC
- NCO/IT R&D